Alpha 2.0
Login Register
» Authors » Martina Schneider

Martina Schneider

Explore the profile of Martina Schneider including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 65
Citations 1448
Followers 0
Related Specialties
Biology
Biochemistry
General Medicine
Top 10 Co-Authors
Christoph Steininger
Susanne Eder-Lingelbach
Romana Hochreiter
Laurent Lagrost
Marie-Theres Kastner
Katrin Dubischar
Sacha I Rothschild
Karin Kosulin
Franz J J Rieder
Meinrad Gawaz
Published In
Lancet Infect Dis
J Biol Chem
Development
Arterioscler Thromb Vasc Biol
J Travel Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents
Buerger V, Hadl S, Schneider M, Schaden M, Hochreiter R, Bitzer A, et al.
Lancet Infect Dis . 2024 Sep; 25(1):114-125. PMID: 39243794
Background: Chikungunya outbreaks have been reported in Brazil since 2014. Adolescents are a sensitive population who would benefit from a prophylactic vaccine. This study assessed the immunogenicity and safety of...
2.
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study
McMahon R, Toepfer S, Sattler N, Schneider M, Narciso-Abraham M, Hadl S, et al.
Lancet Infect Dis . 2024 Aug; 24(12):1383-1392. PMID: 39146946
Background: Chikungunya virus infection can lead to long-term debilitating symptoms. A precursor phase 3 clinical study showed high seroprotection (defined as a 50% plaque reduction of chikungunya virus-specific neutralising antibodies...
3.
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial
Ghadge S, Schneider M, Dubischar K, Wagner L, Kadlecek V, Obersriebnig M, et al.
Lancet Infect Dis . 2024 Jul; 24(11):1275-1286. PMID: 39029481
Background: Incidence rates of Lyme borreliosis, a tickborne disease attributed to infection by Borrelia species, are increasing, and limitations to existing treatments potentiate the possibility of severe outcomes. Nevertheless, there...
4.
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies
Bezay N, Wagner L, Kadlecek V, Obersriebnig M, Wressnigg N, Hochreiter R, et al.
Lancet Infect Dis . 2024 Jun; 24(9):1045-1058. PMID: 38830375
Background: Rising Lyme borreliosis incidence rates, potential for severe outcomes, and limitations in accurate and timely diagnosis for treatment initiation suggest the need for a preventive vaccine; however, no vaccine...
5.
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine
Afferi L, Spahn M, Hayoz S, Strebel R, Rothschild S, Seifert H, et al.
BJU Int . 2024 Mar; 134(3):388-397. PMID: 38456541
Objective: To report on the surgical safety and quality of pelvic lymph node dissection (PLND) in patients treated with radical cystectomy (RC) and PLND for muscle-invasive bladder cancer (MIBC) after...
6.
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, et al.
Eur J Cancer . 2024 Feb; 200:113600. PMID: 38330766
Introduction: The safety and efficacy of first-line durvalumab in PS2 patients with advanced NSCLC is unknown. Here, we present the primary analysis of first-line durvalumab in PS2 patients, unsuitable for...
7.
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†
McMahon R, Fuchs U, Schneider M, Hadl S, Hochreiter R, Bitzer A, et al.
J Travel Med . 2023 Dec; 31(2). PMID: 38091981
Background: The global spread of the chikungunya virus (CHIKV) increases the exposure risk for individuals travelling to or living in endemic areas. This Phase 3 study was designed to demonstrate...
8.
[Individual Needs of the Patient in Breast Reconstruction - Are There Limits to Plastic Surgery?]
Schneider M, Rezaeian F
Praxis (Bern 1994) . 2023 Nov; 112(12):593-598. PMID: 37971482
The breast is essential to a woman's physical integrity. There are numerous techniques for breast reconstruction, so that the needs and limitations of each patient can be respected. The individual...
9.
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17
Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Ozdemir B, Kiss B, et al.
J Clin Oncol . 2023 Aug; 41(33):5131-5139. PMID: 37590894
Purpose: The integration of immunotherapy in the perioperative setting of muscle-invasive urothelial carcinoma (MIUC) appears promising. SAKK 06/17 investigated the addition of neoadjuvant durvalumab to gemcitabine/cisplatin (GC) chemotherapy followed by...
10.
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, et al.
Lancet . 2023 Jun; 401(10394):2138-2147. PMID: 37321235
Background: VLA1553 is a live-attenuated vaccine candidate for active immunisation and prevention of disease caused by chikungunya virus. We report safety and immunogenicity data up to day 180 after vaccination...